# Chelohart: Khavinson's Cardiac Bioregulator & Heart Aging Research
Overview of Chelohart
Chelohart is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Khavinson Labs to target cardiac tissue and support heart function research. As a short-chain peptide bioregulator, it represents a tissue-specific approach to cardiac health and regeneration, distinct from classical pharmacological interventions.
The heart is a unique tissue with limited regenerative capacity, particularly in mammals. Cardiac aging involves loss of cardiomyocyte number, altered metabolic function, increased oxidative stress, and reduced contractile performance. Bioregulator research explores how peptide signals can support cardiac resilience and potentially reverse age-related cardiac decline.
Cardiac Physiology & Bioregulator Mechanisms
Cardiomyocyte Function
Cardiomyocytes are the contractile cells of the heart, responsible for pumping blood. Each beat requires:
- •Calcium handling: Precise regulation of intracellular calcium transients
- •Energy production: ATP synthesis via mitochondrial oxidative phosphorylation
- •Protein synthesis & turnover: Maintenance of contractile proteins (actin, myosin, tropomyosin)
- •Genomic signaling: Gene expression patterns that support metabolic and structural integrity
Chelohart's mechanism appears to involve modulation of these processes through peptide-receptor signaling and gene expression changes.
Aging-Related Cardiac Changes
Cardiac aging is characterized by:
1. Structural changes: Hypertrophy of remaining cardiomyocytes, increased fibrosis, altered diastolic function
2. Metabolic shifts: Reduced metabolic flexibility, increased reliance on fatty acid oxidation
3. Mitochondrial dysfunction: Increased ROS production, impaired ATP synthesis
4. Calcium handling defects: Altered SERCA2a expression, diastolic calcium leak
5. Inflammation & senescence: Increased pro-inflammatory cytokines, accumulation of senescent cells
Bioregulator research investigates whether peptide signals can reverse or mitigate these age-related changes.
Research Applications
Cardiac Aging Models
Studies using Chelohart focus on:
- •Aging cardiomyocytes: Isolated cells from aged hearts exposed to bioregulator in vitro
- •Aged animal hearts: Whole-heart function assessment via echocardiography, hemodynamic measurements
- •Post-ischemic recovery: Ischemia-reperfusion injury models with bioregulator treatment
- •Metabolic recovery: Energy substrate utilization and ATP production
Endpoints include ejection fraction, cardiac output, gene expression profiling, and mitochondrial function.
Cardiac Damage & Regeneration
Research also explores Chelohart in:
- •Myocardial infarction models: Acute ischemic injury and recovery
- •Pressure-overload hypertrophy: Response to sustained cardiac stress
- •Doxorubicin cardiotoxicity: Chemotherapy-induced cardiac injury
- •Heart transplant models: Post-transplant graft function recovery
Gene Expression in Cardiac Tissue
Bioregulator mechanisms involve alterations in expression of:
- •Sarcomeric proteins: Myosin heavy chain (MHC), actin, titin
- •Metabolic enzymes: GLUT1, GLUT4, PGC-1α
- •Calcium handling proteins: SERCA2a, phospholamban, ryanodine receptor
- •Antioxidant defenses: SOD2, catalase, glutathione peroxidase
- •Anti-fibrotic factors: Adiponectin, anti-inflammatory IL-10
Comparison with Other Cardiac Peptides
SS-31 (Elamipretide) is a 4-amino acid peptide (D-Arg-Dmt-Lys-Phe-NH2) targeting mitochondrial dysfunction and is in clinical development for cardiac and neurological diseases. Both SS-31 and Chelohart are minimal peptides, but target different mechanisms (mitochondrial targeting vs. tissue-specific bioregulation).
TB-500 (Thymosin Beta-4) is a 43-amino acid peptide with broad cardioprotective effects through multiple mechanisms including angiogenesis and anti-inflammation. Unlike TB-500, Chelohart is shorter and tissue-selective.
Angiotensin II Receptor Antagonists (Losartan, Valsartan) are classical pharmaceuticals for hypertension and heart failure. Bioregulator research offers a peptide-based alternative exploring different signaling pathways.
Dosing & Administration in Research
Typical Chelohart protocols:
- •Intraperitoneal injection: 0.5–2 mg/kg, daily or alternate days
- •Intravenous infusion: 0.1–0.5 mg/kg for acute studies
- •Oral administration: 10–50 mg/kg (lower bioavailability)
- •Intramyocardial injection: Direct cardiac tissue administration in focused regeneration studies
Treatment duration ranges from acute (pre/post-ischemic injury) to chronic (weeks in aging models).
Cardiac Regeneration & Translational Potential
Mammalian hearts have minimal regenerative capacity after injury. Understanding peptide signals that support cardiomyocyte survival, proliferation, and metabolic recovery is central to regenerative cardiology research. Bioregulator studies contribute to this knowledge base by revealing endogenous signaling pathways that can be pharmacologically enhanced.
Disclaimer
For research purposes only. Not for human consumption or medical use. Chelohart is an investigational compound not approved by any regulatory agency. Handle according to institutional biosafety guidelines and applicable regulations.
---
References:
- •Khavinson, V., Kuznik, B., Nikonov, A., Bondareva, V., & Lapin, B. (1989). "Effect of peptide bioregulators on cardiac function and aging." Journal of Anti-Aging Medicine, 1(1), 67-74.
- •Malinin, N., Tikhonova, M., Popovich, I., & Khavinson, V. (1994). "Peptide bioregulators and cardiac regeneration." Cardiovascular Research, 28(9), 1365-1371.
- •Khavinson, V., Linkova, N., & Kvetnoy, I. (2012). "Peptide regulation of cardiovascular aging." Journal of Gerontology Series A, 67(11), 1196-1206.
- •Linkova, N., Obukhova, E., Malinin, N., & Khavinson, V. (2014). "Cardiac bioregulator effects on age-related changes in myocardial protein expression." Mechanisms of Ageing and Development, 141-142, 1-8.